The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So the first phase of this study Dave talked about on the podcast and it showed that his cohort of lean mass hyperresponders with an average LDL of I think 273 milligrams per deciliter did not have more plaque burden compared to an age matched cohort from Miami heart that had an average LDL of 123.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.